Search Weight Loss Topics:

Page 26«..1020..25262728..40..»

Home » Hgh » Page 26

Heartland Group Holdings Limited (NZSE:HGH), operating in the financial services industry based in New Zealand, saw a double-digit share price rise of over 10% in the past couple of months on the NZSE. As a stock with high coverage by analysts, you could assume any recent changes in the companys outlook is already priced into the stock. However, what if the stock is still a bargain? Lets take a look at Heartland Group Holdingss outlook and value based on the most recent financial data to see if the opportunity still exists.

Check out our latest analysis for Heartland Group Holdings

Great news for investors Heartland Group Holdings is still trading at a fairly cheap price. According to my valuation, the intrinsic value for the stock is NZ$1.65, which is above what the market is valuing the company at the moment. This indicates a potential opportunity to buy low. Whats more interesting is that, Heartland Group Holdingss share price is quite volatile, which gives us more chances to buy since the share price could sink lower (or rise higher) in the future. This is based on its high beta, which is a good indicator for how much the stock moves relative to the rest of the market.

Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Buying a great company with a robust outlook at a cheap price is always a good investment, so lets also take a look at the companys future expectations. With profit expected to grow by 29% over the next couple of years, the future seems bright for Heartland Group Holdings. It looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation.

Are you a shareholder? Since HGH is currently undervalued, it may be a great time to accumulate more of your holdings in the stock. With a positive outlook on the horizon, it seems like this growth has not yet been fully factored into the share price. However, there are also other factors such as capital structure to consider, which could explain the current undervaluation.

Are you a potential investor? If youve been keeping an eye on HGH for a while, now might be the time to make a leap. Its buoyant future outlook isnt fully reflected in the current share price yet, which means its not too late to buy HGH. But before you make any investment decisions, consider other factors such as the strength of its balance sheet, in order to make a well-informed buy.

Price is just the tip of the iceberg. Dig deeper into what truly matters the fundamentals before you make a decision on Heartland Group Holdings. You can find everything you need to know about Heartland Group Holdings in the latest infographic research report. If you are no longer interested in Heartland Group Holdings, you can use our free platform to see my list of over 50 other stocks with a high growth potential.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

Excerpt from:
Is Now The Time To Look At Buying Heartland Group Holdings Limited (NZSE:HGH)? - Simply Wall St

PUBLISHED: 20:35 08 April 2020 | UPDATED: 20:35 08 April 2020

Jake Foxford

Jake Randall has been jailed for six and a half years after stabbing a man in Colchester Picture: ESSEX POLICE

Archant

Email this article to a friend

To send a link to this page you must be logged in.

In the early hours of Sunday, November 17 2019, 20-year-old Jake Randall of Friday Wood Green, Colchester, threatened a woman over the phone who was out in Colchester with friends.

Then later, while she was outside the After Office Hours bar in the town centre, Randall approached her, armed with a knife, and grabbed her friend before stabbing him in the chest.

Witnesses ran over and tried to help and had to fight Randall off and police found him about 1.10am with several cuts and bruises to his face, a blooded nose and a swollen right eye.

Investigating officer PC Avive Martin, of Colchester CID, said the victim was lucky to be alive.

Randall went into Colchester town centre and flew into a rage before stabbing an innocent man to the chest, said PC Martin.

The court heard how the knife was just 4mm from a main artery, which would have been fatal.

The victim spent six days in hospital recovering and suffered from a collapsed lung.

I would like to praise him for his bravery and I hope with Randalls sentence provides some comfort and justice to him.

Randall was sentenced at Chelmsford Crown Court on Monday, April 6, after pleading guilty to grievous bodily harm with intent.

He also received a nine-month sentence for possession of a knife, running concurrently.

He was given a five-year restraining order to help protect two people.

If you value what this gives you, please consider supporting our work. Click the link in the yellow box below for details.

See the original post here:
Colchester hgh street stabber sentenced to more than six years in prison | Latest Suffolk and Essex News - East Anglian Daily Times

Dublin, April 08, 2020 (GLOBE NEWSWIRE) -- The "Hormone Replacement Therapy Market Size, Share & Trends Analysis Report by Product (Estrogen, Human Growth), by Route Of Administration (Oral, Parenteral), by Type Of Disease, by Region, and Segment Forecasts, 2020 - 2027" report has been added to ResearchAndMarkets.com's offering.

The global hormone replacement therapy market size is expected to reach USD 39.6 billion by 2027, expanding at a CAGR of 7.7%. A significant rise in the incidence rate of hormonal disorders in the newborns, adults, and elderly and populations is driving the market. The Prader-Willi syndrome (PWS) affects one in every 15,000 newborns, thereby boosting the demand for the therapy.

Estrogen replacement hormone therapy helps in reducing the vaginal indications of menopause, such as dryness, burning, itching, and pain during intercourse. Estrogen is available in the forms of pill, gel, skin patch, cream or spray form. It is highly successful for treating problematic menopausal night sweats and hot flashes. Around 45% of women between the ages of 40 to 60 years of age were reported taking counseling sessions from a physician regarding the advantages and disadvantages of using hormone replacement therapy (HRT) after menopause.

Growing awareness about menopausal signs and the treatment options is growing the HRT market. Owing to the significant development for ERT, there has been an initiation of very safe treatment options for the patients situated in various geographies of the world. For example, augmentation of innovative drug delivery systems like transdermal estrogen patches and vaginal estrogen drugs.

Further key findings from the report suggest:

Key Topics Covered:

1. Methodology and Scope

2. Executive Summary2.1 Market Outlook2.2 Segment Outlook2.2.1 Product2.2.2 Route of Administration2.2.3 Type of Disease2.2.4 Region2.3 Competitive Insights

3. Market Variables, Trends & Scope3.1 Market Segmentation3.2 Penetration & Growth Prospect Mapping3.2.1 Market Driver Analysis3.2.2 Market Restraint Analysis3.3 Hormone Replacement Therapy Market: Business Environment Analysis Tools3.3.1 Porter's Five Forces Analysis3.3.1.1 Bargaining power of suppliers3.3.1.2 Bargaining power of buyers3.3.1.3 Threat of new entrants3.3.1.4 Competitive rivalry3.3.1.5 Threat of substitutes3.3.2 PESTEL Analysis3.3.2.1 Political & legal3.3.2.2 Economic3.3.2.3 Technological

4. Hormone Replacement Therapy Market: Product Analysis4.1 Hormone Replacement Therapy Product Market Share Analysis, 2019 & 20274.2 Hormone Replacement Therapy Product Market: Segment Dashboard4.3 Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the Product Segment4.3.1 Estrogen Hormone Replacement Therapy4.3.1.1 Estrogen Hormone replacement therapy market, 2016 - 2027 (USD Million)4.3.2 HGH Replacement Therapy4.3.2.1 HGH replacement therapy market, 2016 - 2027 (USD Million)4.3.3 Thyroid Hormone Replacement Therapy4.3.3.1 Thyroid hormone replacement therapy market, 2016 - 2027 (USD Million)4.3.4 Testosterone Hormone Replacement Therapy4.3.4.1 Testosterone hormone replacement therapy market, 2016 - 2027 (USD Million)

5. Hormone Replacement Therapy Market: Route of Administration Analysis5.1 Hormone Replacement Therapy Route of Administration Market Share Analysis, 2019 & 20275.2 Hormone Replacement Therapy Route of Administration Market: Segment Dashboard5.3 Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the Route of Administration Segment5.3.1 Oral5.3.1.1 Oral market, 2016 - 2027 (USD Million)5.3.2 Parenteral5.3.2.1 Parenteral market, 2016 - 2027 (USD Million)5.3.3 Transdermal5.3.3.1 Transdermal market, 2016 - 2027 (USD Million)5.3.4 Others5.3.4.1 Others market, 2016 - 2027 (USD Million)

6. Hormone Replacement Therapy Market: Type of Disease Analysis6.1 Hormone Replacement Therapy Type of Disease Market Share Analysis, 2019 & 20276.2 Hormone Replacement Therapy Type of Disease Market: Segment Dashboard6.3 Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the Type of Disease Segment6.3.1 Menopause6.3.1.1 Menopause market, 2016 - 2027 (USD Million)6.3.2 Hypothyroidism6.3.2.1 Hypothyroidism market, 2016 - 2027 (USD Million)6.3.3 Male Hypogonadism6.3.3.1 Male hypogonadism market, 2016 - 2027 (USD Million)6.3.4 Growth Hormone Deficiency6.3.4.1 Growth hormone deficiency market, 2016 - 2027 (USD Million)6.3.5 Others6.3.5.1 Others market, 2016 - 2027 (USD Million)

7. Hormone Replacement Therapy Market: Regional Analysis7.1 Hormone Replacement Therapy Regional Market Share Analysis, 2019 & 20277.2 Hormone Replacement Therapy Regional Market: Segment Dashboard7.3 Regional Market Snapshot (Market Size, CAGR, Top Verticals, Key Players, Top Trends)7.4 Market Size, & Forecasts, and Trend Analysis, 2016 to 20277.4.1 North America7.4.1.1 North America hormone replacement therapy market, 2016 - 2027 (USD Million)7.4.1.1.1 U.S.7.4.1.1.1.1 U.S. hormone replacement therapy market, 2016 - 2027 (USD Million)7.4.1.1.2 Canada7.4.1.1.2.1 Canada hormone replacement therapy market, 2016 - 2027 (USD Million)7.4.2 Europe7.4.2.1 Europe Hormone Replacement Therapy market, 2016 - 2027 (USD Million)7.4.2.1.1 U.K.7.4.2.1.1.1 U.K. hormone replacement therapy market, 2016 - 2027 (USD Million)7.4.2.1.2 Germany7.4.2.1.2.1 Germany hormone replacement therapy market, 2016 - 2027 (USD Million)7.4.3 Asia Pacific7.4.3.1 Asia Pacific hormone replacement therapy market, 2016 - 2027 (USD Million)7.4.3.1.1 Japan7.4.3.1.1.1 Japan hormone replacement therapy market, 2016 - 2027 (USD Million)7.4.3.1.2 China7.4.3.1.2.1 China hormone replacement therapy market, 2016 - 2027 (USD Million)7.4.4 Latin America7.4.4.1 Latin America hormone replacement therapy market, 2016 - 2027 (USD Million)7.4.4.1.1 Brazil7.4.4.1.1.1 Brazil hormone replacement therapy market, 2016 - 2027 (USD Million)7.4.4.1.2 Mexico7.4.4.1.2.1 Mexico hormone replacement therapy market, 2016 - 2027 (USD Million)7.4.5 Middle East and Africa (MEA)7.4.5.1 MEA hormone replacement therapy market, 2016 - 2027 (USD Million)7.4.5.1.1 South Africa7.4.5.1.1.1 South Africa hormone replacement therapy market, 2016 - 2027 (USD Million)7.4.5.1.2 Saudi Arabia7.4.5.1.2.1 Saudi Arabia hormone replacement therapy market, 2016 - 2027 (USD Million)

8. Competitive Analysis8.1 Strategic Framework/ Competition Categorization (Key innovators, Market leaders, emerging players8.2 Vendor Landscape8.3 Company market position analysis (Geographic Presence, Product Portfolio, Strategic Initiatives, Employee Strength)8.4 Company Profiles

Companies Mentioned

Story continues

For more information about this report visit https://www.researchandmarkets.com/r/ta9bk1

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

Read this article:
Global Hormone Replacement Therapy Market (2020 to 2027) - by Product, Route of Administration, Type of Disease, Region and Segment Forecasts - Yahoo...

The thymus is the principal organ of T cell production and Growth hormone is a potent regulator of thymic function.

Evidence suggests a two way correlation between the neuroendocrine system and immune system. It is well known that lymphoid organs such as the thymus, the spleen and peripheral blood generate growth hormone. GH receptors are found on distinct groups of lymphocytes.

GH encourages proliferation of T and B cells and synthesis of immunoglobulin. It also accelerates the evolution of myeloid progenitor cells while also modulating cytokine response.

Numerous evidence from Research has reported the bi-directional relationship between the Growth Hormone and the Immune System. In both in vivo and in vitro studies in animal and human studies, interactions have been evidenced in between growth hormone and the immune system.

With age, the thymus gland begins to atrophy. Aging related thymus atrophy results in increased incidence of autoimmune and infectious conditions in the human body.Parallel to the thymus gland shrinkage, a decline in the number of T-cells and immune factors like Interleukin 2 occurs.

As researchers debated the role of growth hormone in immunity and thymic function, a study was conducted to determine whether true thymic function can be induced in HIV infected adults by Growth Hormones. The study also aimed to confirm that such induction is actually driven by growth hormone. Additionally, the study planned to evaluate whether thymic function plays a role in sustaining the T cell compartment.

Participants: Twenty-four volunteers were enrolled in the 2 year study.

Methodology: All participants received 12 months of treatment with human growth hormone. Participants were randomly assigned to one of two study groups. Twelve participants (Group 1) received growth hormone during the first year of the study. Twelve participants (Group 2) were enrolled in an observational control group that crossed over to growth hormone treatment after 1 year. Each Study visit included physical exams, blood tests, CT scans, PET scans, and DEXA scans.

Conclusion: GH treatment was associated with increased circulating levels of IGF-1.

GH treatment resulted in significant radiographic changes in the thymus gland by therapy duration of 6 months, as well as sizeable increases in circulating naive T cells, signifying improved thymic function.

GH treatment is associated with increase in thymopoiesis and recovery in peripheral T cells. Many of the immune effects seem to be mediated by IGF-1, therefore it is possible that GH or IGF-1 also stimulates gains in T cell number by enhancing expansion of peripheral T cells synthesis.

In immunodeficient and aging population, HGH therapy may play a particularly important role in improving thymus gland function and as a result the ability of the immune system to fight viral, bacterial and fungal infections.

Growth Hormone to Increase Immune Function in People With HIV

Effect of growth hormone (GH) on the immune system.

More here:
Growth Hormone Increases Immune Function in Immune Deficient and Aging Population - Gilmore Health News

Human Growth Hormone (HGH) therapy has been around for decades but has been reserved for specific patients. Those with HIV or children with a hormone deficiency were some of the patients who benefitted. However, in recent years, a new focus has targeted therapy to help adults with hormone deficiencies.

HGH is aproteinproduced by the pituitary gland. The hypothalamus and hormones in the intestinal tract and pancreas help to balance it. It thrusts into production during sleep, exercise or trauma with more produced at night than in the daytime, given rising to the term beauty rest as the hormone is also linked to anti-aging.

Production of the hormone decreases as we age and that can lead to problems typically associated with getting older like:

The purpose of the growth hormone in children is to help bones and muscles grow. It also helps with organ function. Hormone therapy in adults is linked to:

Manycelebritiesare reportedly using hormones, but many are doing it illegally. They do it for anti-aging or for muscle mass. This is something all doctors warn against because the growth hormone has some possible side effects including water retention, high blood sugar, and joint and muscle pain. Plus, for those who have normal hormone levels, illegal use of it and then stopping will cause your body to produce less. That leaves you worse off than before.

Most celebrities who take legal hormone therapy dont like to talk about it for a variety of reasons. Its a controversial subject and many deem it private. However, a handful of aging stars have come out to talk about their decision to go on legal hormone therapy.

Benefits of therapy were noted in a New EnglandJournal of Medicine study. Men on six months of therapy increased their muscle mass 8.8 percent and reduced body fat by more than 14 percent. While it is linked to anti-aging, there are no conclusive studies to prove that.

Those considering hormone therapy must get a prescription in order to go to Hormone Clinic. That includes going to a doctor, getting a blood test and probably some specialized testing on the pituitary gland and hypothalamus. Or, you can just call for free consultation toHGH Therapy Clinicand get all the instructions. This clinic, as long as other top-rated clinics, does not provide therapy for bodybuilders and only provides it to those with a hormone deficiency.

This therapy is administered by injection and should be part of a routine health management plan under a doctors care to avoid side effects. For more information about hormone therapy, fill in the contact form and the knowledgeable advisor will call you back.

More here:
Celebrities that take HGH: Why do they need it? - - VENTS Magazine

COPENHAGEN, Denmark, March 25, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced that the company will hold a conference call and live webcast onWednesday, April 1, 2020at4:30 p.m. Eastern Time(ET) to review its 2019 financial results and provide a business update.

Conference Call Details

A live webcast of the conference call will be available on the Investors and News section of theAscendis Pharmawebsite atwww.ascendispharma.com. A webcast replay will be available on this website shortly after conclusion of the event for 30 days.

About Ascendis Pharma A/S

Ascendis Pharmais applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients lives. Guided by its core values of patients, science and passion, the company utilizes its TransCon technologies to create new and potentially best-in-class therapies.

Ascendis Pharma currently has a pipeline of three independent endocrinology rare disease product candidates in clinical development and is advancing oncology as its second therapeutic area of focus. The company continues to expand into additional therapeutic areas to address unmet patient needs.

Ascendis is headquartered in Copenhagen, Denmark, with offices in Heidelberg, Germany and Palo Alto, California.

For more information, please visit http://www.ascendispharma.com.

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) our ability to apply our platform technology to build a leading, fully integrated biopharma company, (ii) our expectations regarding our ability to create new and potentially best-in-class therapies and (iii) our product pipeline and expansion into additional therapeutic areas. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that we make, including the following: unforeseen safety or efficacy results in our TransCon hGH, TransCon PTH and TransCon CNP or other development programs; unforeseen expenses related to the development of TransCon hGH, TransCon PTH and TransCon CNP or other development programs, general and administrative expenses, other research and development expenses and our business generally; delays in the development of TransCon hGH, TransCon PTH and TransCon CNP or other development programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; dependence on third party manufacturers to supply study drug for planned clinical studies; and our ability to obtain additional funding, if needed, to support our business activities. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to our business in general, see our current and future reports filed with, or submitted to, theU.S. Securities and Exchange Commission(SEC), including our Annual Report on Form 20-F for the year endedDecember 31, 2018, which we filed with theSEConApril 3, 2019. Forward-looking statements do not reflect the potential impact of any future in-licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments we may enter into or make. We do not assume any obligation to update any forward-looking statements, except as required by law.

Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma group. March 2020 Ascendis Pharma A/S.

The rest is here:
Ascendis Pharma A/S Announces Full Year 2019 Financial Results and Business Update Conference Call on April 1 - GlobeNewswire

New York, March 30, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Infrared Aerial Camera Market 2020-2024" - https://www.reportlinker.com/p05878574/?utm_source=GNW Our reports on global infrared aerial camera market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by increasing use of infrared aerial cameras in UAVs. In addition, increasing use of infrared aerial cameras in solar farms is anticipated to boost the growth of the global infrared aerial camera market as well.

Market Segmentation The global infrared aerial camera market is segmented as below: Application: Commercial Military

Geographic Segmentation: North America APAC Europe South America MEA

Key Trends for global infrared aerial camera market growth This study identifies increasing use of infrared aerial cameras in solar farms as the prime reasons driving the global infrared aerial camera market growth during the next few years.

Prominent vendors in global infrared aerial camera market We provide a detailed analysis of around 25 vendors operating in the global infrared aerial camera market 2020-2024, including some of the vendors such as DIAS Infrared GmbH, FLIR Systems Inc., HGH Systemes Infrarouges SAS, Infrared Cameras Inc., InfraTec GmbH, Jenoptik AG, L3Harris Technologies Inc., Leonardo Spa, SZ DJI Technology Co. Ltd. and Yuneec Europe GmbH . The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.Read the full report: https://www.reportlinker.com/p05878574/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

See more here:
The Global Infrared Aerial Camera Market is expected to grow by USD 362.77 mn during 2020-2024, progressing at a CAGR of 8% during the forecast period...

- Kalbe Genexine Biologics (KG Bio) will receive right of first negotiation for an exclusive license to potentially commercialize I-Mabs TJD5, in Southeast Asia and other territories

- Partnership to include right of first negotiation on an additional I-Mab-discovered product candidate to be agreed upon by both parties

-Total potential value of TJD5 agreement up to approximately $340 million

SHANGHAI, China, and ROCKVILLE, MD., March 30, 2020 (GLOBE NEWSWIRE) -- I-Mab (the Company)(IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders, today announced a strategic partnership with Kalbe Genexine Biologics (KG Bio), a joint venture of Kalbe Farma Tbk (Kalbe), and Genexine, Inc. (Genexine). Under the terms of the agreement, KG Bio will receive a right of first negotiation for an exclusive license for the commercialization of two I-Mab discovered product candidates: TJD5, a highly differentiated anti-CD73 antibody in Phase 1 development for advanced solid tumors, and an I-Mab product candidate to be agreed upon by both parties.

With the agreement, KG Bio will have a right of first negotiation for exclusive rights to commercialize these two product candidates in the ASEAN (Brunei Darussalam, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand and Vietnam) and MENA (Algeria, Bahrain, Djibouti, Egypt, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon, Libya, Malta, Morocco, Oman, Qatar, Saudi Arabia, Syria, Tunisia, United Arab Emirates, Palestine, and Yemen) regions, as well as Sri Lanka.

This partnership recognizes the potential of our internally-discovered anti-CD73 antibody TJD5 in immuno-oncology, and its clear clinical differentiation related to a novel epitope of CD73, said Dr. Jingwu Zang, Founder, Honorary Chairman and Director of I-Mab. We are pleased to enter into this strategic partnership with the Kalbe corporate family, which is a leader in commercializing innovative therapies in Southeast Asia and other key strategic markets and deepen our relationship with Genexine. We believe this partnership will expand the commercialization potential of TJD5 and other candidates in our portfolio.

I-Mab has a highly innovative and globally competitive pipeline epitomized by products with best-in-class potential such as TJD5. With this novel partnership KG Bio will further strengthen its immuno-oncology portfolio. We are determined to maximize the potential of these products by leveraging our commercial capabilities and presence in the ASEAN, Middle East and North Africa (MENA) regions as well as Sri Lanka, where demand for breakthrough therapies is growing significantly, commented Sie Djohan, President Director of KG Bio.

If and when I-Mab and KG Bio enter into the definitive licensing agreement for TJD5, I-Mab would be eligible to receive from KG Bio an aggregate amount of up to approximately $340 million, including an upfront payment and subsequent payments conditional upon achieving certain development and commercial milestones. KG Bio would pay I-Mab tiered royalties in the low to mid-teen percentages on net sales from the ASEAN and MENA regions, as well as Sri Lanka.

About TJD5

TJD5 is a differentiated, humanized monoclonal antibody against CD73. CD73 is expressed in tumors and plays a critical role in suppressing immune cells in tumor micro-environment. By binding to a novel epitope and inhibiting CD73, TJD5 is believed to reshape the immuno-suppressive tumor micro-environment and increase T-cell anti-tumor activity. When combined with a PD-L1 antibody in vivo, TJD5 achieved better anti-tumor efficacy. TJD5 is currently being evaluated in a Phase 1, dose-escalation clinical trial in patients with advanced solid tumors in the United States.

About Kalbe Genexine Biologics (KG Bio)

KG Bio is a joint venture between Kalbe Farma of Indonesia and Genexine of South Korea. KG bio is focused on clinical development and the commercialization of novel biologics and monoclonal antibodies in ASEAN, Asia Pacific and MENA. Through innovative technological platform that ensures affordable and high-quality products, KG Bio aims to provide innovative biologic and immuno-oncology products, and better solutions in treating human diseases.

Story continues

About Kalbe

PT Kalbe Farma Tbk was established in 1966 and is one of the largest publicly-listed pharmaceutical companies in Southeast Asia. It has four main divisions including prescription pharmaceuticals, consumer health, nutritionals and distribution with over one million outlets. Kalbe Farma currently has more than 35 subsidiaries and 12 production facilities with international standards, supported by around 17,000 employees, spread in 76 branches across Indonesia. Since 1991, its shares have been listed on the Indonesia Stock Exchange (IDX:KLBF)

About Genexine, Inc.

Genexine, Inc., listed on KOSDAQ (095700) since 2009, is a leading biotherapeutics company focused on immuno-oncology and orphan disease. Genexine has a robust pipeline of products in the clinical stage, e.g. Hyleukin-7, HyTropin (GX-H9), Papitrol (GX-188E), etc. based on long-acting Fc fusion technology and therapeutic DNA vaccine technology. Genexine has completed multinational phase II trials and is preparing to apply IND of US Phase III trial for HyTropin (long-acting human growth hormone, hGH-hyFc). Papitrol, a therapeutic DNA vaccine for HPV-associated diseases is under Phase II trial in combination with Keytruda (MSD) for cervical cancer. Founded in 1999, Genexine has over 180 employees, and half of them are scientists with MSc, or Ph.D. Genexine is located in Pangyo Techno Valley near Seoul, Korea.

About I-Mab

I-Mab (IMAB) is a dynamic, global biotech company exclusively focused on developing novel or highly differentiated biologics in the therapeutic areas of immuno-oncology and autoimmune diseases. I-Mabs mission is to bring transformational medicines to patients through innovation. I-Mabs innovative pipeline of more than 10 clinical and pre-clinical stage drug candidates is driven by the Companys Fast-to-PoC (Proof-of-Concept) and Fast-to-Market development strategies through internal R&D and global partnerships. The Company is on track to become a fully integrated end-to-end global biopharmaceutical company with cutting-edge discovery platforms, proven pre-clinical and clinical development expertise, and world-class GMP manufacturing capabilities. I-Mab has offices in China and the United States. For more information, please visit http://ir.i-mabbiopharma.com

Forward Looking Statements

This press release includes certain disclosures which contain forward-looking statements. You can identify forward-looking statements because they contain words such as anticipate and expected. Forward-looking statements are based on I-Mabs current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in filings with the U.S. Securities and Exchange Commission. I-Mab undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

For more information, please contact:

I-MabJielun Zhu, CFOE-mail: jielun.zhu@i-mabbiopharma.comOffice line: +86 21 6057 8000

Investor Inquiries:

Burns McClellan, Inc. (Americas and Europe)Steve KlassE-mail: sklass@burnsmc.comOffice line: +1 212 213 0006

The Piacente Group, Inc. (Asia)Emilie WuE-mail: emilie@thepiacentegroup.comOffice line: + 86 21 6039 8363

Media Inquiries (Americas and Europe):

Burns McClellan, Inc.Ryo Imai / Robert Flamm, Ph.D.E-mail: rimai@burnsmc.com / rflamm@burnsmc.comOffice line: +1 212 213 0006

See the original post:
I-Mab Enters into Strategic Regional Partnership with Kalbe Genexine Biologics for Commercialization Rights of CD73 Antibody, TJD5, for...

The Human Growth Hormone (HGH) market is expected to grow worth of USD +9 Billion and at a CAGR of 8% over the forecast period 2020-2026.

The Research Insights proclaims the addition of new statistical data titled a global Human Growth Hormone (HGH) market. This informative report incorporates qualitative and quantitative analysis of the global market for the elaboration of the market. It offers a systematic evaluation of the market by analyzing it.

Introduction of novel therapies, growing R&D activities, and rising awareness for the diagnosis and treatment of growth hormone (GH) disorders are expected to drive the market. Rise in the number of regulatory approvals and launch of novel hGH therapies are expected to fuel the market over the forecast period.

Request a Sample Copy of this Report @:

https://www.theresearchinsights.com/request_sample.php?id=21385

Top Key Players:

Merck Co. Inc

Eli Lilly and Company

Genentech?Inc.

Novo Nordisk

Sandoz International GmbH

Ferring Holding SA

Ipsen

Geographically, the global market fragmented across several regions such as North America, Latin America, Asia-Pacific, Africa, and the Middle East on the basis of different business verticals. In the era of developing and developed countries are holding the highest share. A clear picture of the global Human Growth Hormone (HGH) market has been provided by presenting the market with distinctive info graphics.

The report proficiently inspects the most significant inconspicuous components of the Global Human Growth Hormone (HGH) Market with the help of an extensive and specific examination. Described in a ground-up way, the report demonstrates an expansive framework of the market in light of the components that are anticipated to have an amazing and quantifiable impact on the markets formative conditions over the assessed time span.

Ask for Upto 40% Discount:

https://www.theresearchinsights.com/ask_for_discount.php?id=21385

Table of Content:

Global Human Growth Hormone (HGH) Market Research Report 2020-2026

Chapter 1: Industry Overview

Chapter 2: Human Growth Hormone (HGH) Market International and China Market Analysis

Chapter 3: Environment Analysis of Market.

Chapter 4: Analysis of Revenue by Classifications

Chapter 5: Analysis of Revenue by Regions and Applications

Chapter 6: Analysis of Human Growth Hormone (HGH) Market Revenue Market Status.

Chapter 7: Analysis of Industry Key Manufacturers

Chapter 8: Sales Price and Gross Margin Analysis of Market.

Chapter 9: Continue To TOC

To Get More Information, Enquiry @:

https://www.theresearchinsights.com/enquiry_before_buying.php?id=21385

*If you have any special requirements, please let us know and we will provide you the report as you want*

About us

The Research Insights A global leader in analytics, research and advisory that can assist you to renovate your business and modify your approach. With us, you will learn to take decisions intrepidly. We make sense of drawbacks, opportunities, circumstances, estimations and information using our experienced skills and verified methodologies. Our research reports will give you an exceptional experience of innovative solutions and outcomes. We have effectively steered businesses all over the world with our market research reports and are outstandingly positioned to lead digital transformations. Thus, we craft greater value for clients by presenting advanced opportunities in the global market.

Contact us

Robin

Sales manager

Contact number: +91-996-067-0000

[emailprotected]

https://www.theresearchinsights.com/

View original post here:
Human Growth Hormone (HGH) Market 2020-2026 Rising Awareness For The Diagnosis Drives The Growth With Merck Co. Inc, Eli Lilly and Company,...

Human Growth Hormone impacts the cells in a manner that advances the development of body tissues. It is discharged all through life anyway its belongings are generally sensational during adolescence. HGH at last lessens muscle to fat ratio and builds bulk. Be that as it may, how can it work? Furthermore, in what capacity will it help us in accomplishing sound and characteristic weight reduction without the need to slim down? With every supper we experience a three phase pattern of gala and quick. In the principal hour subsequent to eating glucose rises and insulin is discharged. This energizes stockpiling of overabundance starches as fats. After the second hour HGH is discharged and the degrees of insulin and glucose begin to fall. It is at this stage the hormone demonstrations to develop muscle protein which is upgraded by the nearness of insulin.

The last stage happens over four hours subsequent to eating the fasting stage. The grouping of hormone stays high while the insulin has nearly vanished this permits the hormone to act exclusively to activate the bodys fat stores for consuming as fuel. In the youthful the degrees of development hormone are high concerning insulin. The human development hormone goes about as a brake on insulin keeping its fat creation at any rate for example insulin makes fat whilekrople idealica do utraty wagi separates fat to use as vitality Insulin is a basic hormone required for the digestion of sugar we cannot make do without it. Insulin additionally attempts to invigorate muscle development however to an a lot lesser degree than HGH. In the event that levels are too low insulin is allowed to transform each calorie you do not consume into fat for sometime in the future.

On the off chance that you need to guarantee a long life and solid future for you and your children, at that point you should guarantee that you embrace and follow a sound, regular and nutritious eating regimen limiting the utilization of handled nourishments. By permitting 4 hours among suppers and seriously confining snacks between dinners you will guarantee that the three phase cycle is followed and that the normal harmony among HGH and insulin is kept up so the two of them cooperate inside the dining experience quick cycle. Recall when HGH and Insulin are in the circulatory system together they help to invigorate protein combination and development of bulk. Simultaneously the more significant levels of human development hormone work to square insulins fat stockpiling impact along these lines during stage 3 for example 4 hours in the wake of eating when insulin vanishes from the circulation system HGH would then be able to process the fat without impedance. Corpulence is the common result of following an unnatural and undesirable way of life.

See the original post:
Comprehend the healthy weight maintenance - The Cowley Press

Page 26«..1020..25262728..40..»

Home » Hgh » Page 26